Regulation of GLP-1 and Glucagon Receptor Function by β-Arrestins in Metabolically Important Cell Types
Biochemistry · 04.03.2025 · 64 (5) · 978-986
DOI: 10.1021/acs.biochem.4c00867 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemistry, online erschienen am 21.02.2025. Verfasst von Liu Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland…. Hauptthemen laut MEDLINE: Receptors, Glucagon, Glucagon-Like Peptide 1, beta-Arrestins, Glucagon-Like Peptide-1 Receptor. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 84 Literaturangaben. Gefördert von: National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Glucagon-like peptide-1 (GLP-1) and glucagon (GCG) are polypeptides derived from a common precursor (preproglucagon) that modulates the activity of numerous cell types involved in regulating glucose and energy homeostasis. GLP-1 and GCG exert their biological functions via binding to specific G protein-coupled receptors (GLP-1Rs and GCGRs). Ligand-activated GLP-1Rs and GCGRs preferentially activate the heterotrimeric G protein Gs, resulting in increased cytosolic cAMP levels. However, activation of the two receptors also leads to the recruitment of β-arrestin-1 and -2 (βarr1 and βarr2, respectively) to the intracellular surface of the receptor proteins. The binding of β-arrestins to the activated receptors contributes to the termination of receptor-stimulated G protein coupling. In addition, receptor-β-arrestin complexes can act as signaling nodes in their own right by modulating the activity of many intracellular signaling pathways. In this Review, we will discuss the roles of βarr1 and βarr2 in regulating key metabolic functions mediated by activated GLP-1Rs and GCGRs. During the past decade, GLP-1R agonists have emerged as highly efficacious antidiabetic and antiobesity drugs. Moreover, dual agonists that stimulate both GLP-1Rs and GCGRs are predicted to offer additional therapeutic benefits as compared to GLP-1R agonist monotherapy. We will summarize and try to synthesize a series of studies suggesting that the development of G protein-biased GLP-1R and/or GCGR agonists, which do not lead to the recruitment of β-arrestins, may lead to even more efficacious therapeutic agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892, United States.
ORCID-Profile: Jürgen Wess
Förderung
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Liu, L., Rashid, M., & Wess, J. (2025). Regulation of GLP-1 and Glucagon Receptor Function by β-Arrestins in Metabolically Important Cell Types. Biochemistry, 64(5), 978-986. https://doi.org/10.1021/acs.biochem.4c00867
Vancouver
Liu L, Rashid M, Wess J. Regulation of GLP-1 and Glucagon Receptor Function by β-Arrestins in Metabolically Important Cell Types. Biochemistry. 2025;64(5):978-986. doi:10.1021/acs.biochem.4c00867
BibTeX
@article{Liu2025,
author = {Liu, Liu and Rashid, Misbah and Wess, Jürgen},
title = {Regulation of GLP-1 and Glucagon Receptor Function by β-Arrestins in Metabolically Important Cell Types},
journal = {Biochemistry},
year = {2025},
volume = {64},
number = {5},
pages = {978--986},
doi = {10.1021/acs.biochem.4c00867}
}
EUVIMED